Broncus Holding Corp. (2216) AI Stock Analysis

• Market Cap: HK$1.31B
• Dividend Yield: N/A
• Average Volume (3M): 2.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: -30.60%
• EPS Growth: 28.61%
• Country: HK
• Employees: 200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 528,237,060
• 10 Day Avg. Volume: 1,907,700
• 30 Day Avg. Volume: 2,030,864
• PEG Ratio: 0.05
• Price to Book (P/B): 0.22
• Price to Sales (P/S): 4.56
• P/FCF Ratio: -3.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Neutral
• Price Target: HK$2.50 ▼(-1.57% Downside)

Broncus Holding Corp.'s stock score is primarily impacted by its challenging financial performance, characterized by declining revenues and significant losses. Technical analysis further supports a bearish outlook, and valuation metrics highlight ongoing financial difficulties. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

High Gross Profit Margin

A high gross profit margin indicates efficient cost management and pricing power, which can support profitability as revenue stabilizes.

Strong Equity Position

A strong equity position with minimal leverage provides financial stability and flexibility for future investments and growth.

Innovative Product Focus

Focus on innovative medical technologies for lung diseases positions the company to benefit from growing healthcare needs and advancements.

Negative Factors

Revenue Decline

Ongoing revenue decline suggests challenges in market demand or competitive positioning, impacting long-term growth prospects.

Cash Flow Challenges

Significant cash flow challenges limit the company's ability to invest in growth opportunities and manage operational needs effectively.

Profitability Issues

Severe profitability issues with negative margins indicate operational inefficiencies and potential difficulties in achieving sustainable earnings.

Broncus Holding Corp. Business Overview & Revenue Model

Company Description

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

How the Company Makes Money

Broncus Holding Corp. makes money by developing and selling its proprietary medical devices and solutions to healthcare providers and institutions. Its revenue model primarily consists of direct sales of its diagnostic and therapeutic products, as well as potential licensing agreements and partnerships with other medical technology firms. The company may also engage in research collaborations and receive funding or grants related to its innovative work in the pulmonary field. These partnerships and collaborations help Broncus expand its market reach and accelerate the commercialization of new technologies.

Broncus Holding Corp. Financial Statement Overview

Summary

Broncus Holding Corp. faces significant financial challenges, including declining revenues, persistent net losses, and negative cash flow. While the company maintains a strong gross profit margin and equity position, these are overshadowed by severe profitability and liquidity issues.

Income Statement

Broncus Holding Corp. displays a challenging income statement profile with consistent revenue declines from 2021 to 2024, despite experiencing a peak in 2020. The gross profit margin remains high at around 75.5% in 2024, reflecting efficient cost management relative to revenue. However, significant net losses and negative EBIT and EBITDA margins, particularly in 2024 with a net profit margin of -188.23%, indicate persistent profitability issues.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 96.36% in 2024, suggesting good asset coverage by equity. The debt-to-equity ratio is low at 0.0019, indicating minimal leverage. However, the company has experienced declines in total assets and stockholder equity over time, posing potential risks if trends continue.

Cash Flow

Broncus Holding Corp. faces significant cash flow challenges. The operating cash flow to net income ratio indicates a disconnect between earnings and cash flow generation, as evidenced by zero operating cash flow in 2024. The lack of free cash flow growth and historically negative free cash flow further stress the company's liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.08M	8.13M	10.26M	9.41M	10.89M	3.26M
Gross Profit	4.40M	6.14M	7.23M	7.32M	8.74M	2.51M
EBITDA	-20.69M	-18.96M	-25.06M	-30.58M	-233.31M	-45.95M
Net Income	-15.15M	-15.30M	-28.09M	-28.04M	-236.18M	-48.24M
Balance Sheet
Total Assets	165.67M	175.90M	195.81M	221.94M	252.81M	39.88M
Cash, Cash Equivalents and Short-Term Investments	130.52M	139.11M	156.88M	187.91M	227.21M	18.79M
Total Debt	47.00K	318.00K	2.35M	1.47M	1.95M	6.12M
Total Liabilities	5.29M	6.42M	10.44M	8.48M	10.39M	162.32M
Stockholders Equity	160.38M	169.48M	185.37M	213.46M	242.42M	-120.51M
Cash Flow
Free Cash Flow	-5.99M	-10.32M	-26.84M	-31.81M	-33.38M	-16.76M
Operating Cash Flow	-5.91M	-10.00M	-26.13M	-30.95M	-31.49M	-15.59M
Investing Cash Flow	-21.16M	-25.91M	5.49M	-87.57M	-1.75M	-1.09M
Financing Cash Flow	-3.21M	-1.02M	-1.46M	-572.00K	241.82M	32.23M

Broncus Holding Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 2.54 is below the 20-day moving average (MA) of 2.59, below the 50-day MA of 2.83, and above the 200-day MA of 2.18, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 42.42 is Neutral, neither overbought nor oversold. The STOCH value of 32.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.

Broncus Holding Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	55 Neutral	HK$1.92B	41.24	3.84%	―	32.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2170	44 Neutral	HK$588.08M	―	-20.60%	―	11.43%	4.88%
2235	44 Neutral	HK$2.81B	―	-1.39%	―	49.86%	80.35%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
2500	41 Neutral	HK$1.13B	-1.62	-26.80%	―	-8.56%	-14.84%
2216	40 Neutral	HK$1.31B	-10.19	-8.93%	―	-30.60%	28.61%

Broncus Holding Corp. Corporate Events

Broncus Holding Corp. Announces Share Issue to Fund Expansion

Broncus Holding Corp. announced a proposed issue of shares under a general mandate, agreeing to allot and issue 105,108,015 subscription shares at HK$3.11 per share. This move, representing approximately 19.90% of the company’s issued share capital, is expected to raise gross proceeds of HK$326.9 million, which will support the company’s expansion in the medical devices industry. The completion of the subscription agreements is subject to certain conditions, and stakeholders are advised to exercise caution.

The most recent analyst rating on (HK:2216) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.

Broncus Holding Corp. Reports Interim Results and Launches Innovative Lung Cancer Therapy

Broncus Holding Corp. announced its interim results for the first half of 2025, revealing a significant decline in revenue and gross profit compared to the previous year. Despite the financial downturn, the company achieved a milestone with the approval and launch of its BroncAblate® system in China, marking a significant advancement in lung cancer treatment. The system, which has been validated by clinical studies, represents a breakthrough in ultra-minimally invasive therapy, offering new treatment options for patients worldwide. The commercialization process, including reimbursement and procurement, is progressing smoothly, indicating a positive outlook for future operations.

The most recent analyst rating on (HK:2216) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.

Broncus Holding Corp. Schedules Board Meeting for Interim Results

Broncus Holding Corporation has announced that its Board of Directors will convene on August 28, 2025, to review and approve the unaudited interim financial results for the first half of the year. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming months.

Broncus Holding Corp. Grants Performance-Based Awards to Employees

Broncus Holding Corporation announced the grant of 352,683 awards under its RSU Scheme to seven employees, representing approximately 0.07% of the total shares in issue. These awards are part of a performance-based vesting schedule aimed at rewarding employee contributions and aligning their interests with the company’s long-term growth. The awards will vest within three months, contingent on meeting specific performance targets. The initiative underscores the company’s commitment to retaining talent and fostering growth, with a significant number of shares still available for future grants under the scheme.